CEO Nicolas Poirier on OSE Immunotherapeutics Latest IL-7 Data

Citeline Podcasts
03/04/2025 16 min
CEO Nicolas Poirier on OSE Immunotherapeutics Latest IL-7 Data

Listen "CEO Nicolas Poirier on OSE Immunotherapeutics Latest IL-7 Data"

Descargar episodio Ver en sitio original

Episode Synopsis

OSE Immunotherapeutics' CEO Nicolas Poirier talks about the company's IL-7 receptor agonist, lusvertikimab, recent data presented at The European Crohn's and Colitis Organization congress, commercialization and development strategy and the future of IBD therapy.

More episodes of the podcast Citeline Podcasts

Datamonitor Healthcare Podcast: ESMO 2025 12/11/2025
Scrip 五件必知要闻: 药闻周析 - 全球制药风云聚焦 (Chinese-language podcast) 10/11/2025
Scrip's Five Must-Know Things - Nov. 10, 2025 10/11/2025
Drug Fix: Examining George Tidmarsh’s Departure As Head Of US FDA’s Drug Center 07/11/2025
Podcast: Beyond The Checkpoint — Next-Gen Strategies In Immuno-Oncology 06/11/2025
Scrip 五件必知要闻: 药闻周析 - 全球制药风云聚焦 (Chinese-language podcast) 04/11/2025
Scrip's Five Must-Know Things - Nov. 4, 2025 04/11/2025
Drug Fix: US FDA Streamlines Biosimilar Development Requirements, Clarifies Inspection Reform 31/10/2025
Decoding Cell Differentiation: How AI Foundation Models Are Reshaping Regenerative Medicine 31/10/2025
Scrip M&A Podcast: What's Next For Dealmaking In The Obesity Space? 31/10/2025
© 2003-2025 ZARZA | AHEAD OF OUR TIME
privacy policy
In God we trust In God we trust
PreSales Questions? Click Here
or call our toll-free line at +1-888-5002068 Miami, Florida, USA